A small molecule is a small, chemically manufactured compound with a low molecular weight. Small molecule drugs help regulate a biological target such as an enzyme, channel or receptor to modify a disease process.
The large majority of drugs on the market today are small molecules and most are delivered orally. Small molecule drugs are part of what Syncona calls, the “First Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.
Key facts*
£55m
Value of portfolio
5
Syncona Board seats
2
New investments in the year
Our small molecule portfolio companies
The small molecule pipeline
Drug discovery
Pre-clinical
Clinical
Our domain areas
Syncona has deep domain expertise across four key therapeutic areas.
*Unless stated all financials at 31 December 2022.